best glp-1 agonists for weight loss Decoding Medications The New Weight Management Meds

In addition, even if our results of operations, financial condition and liquidity, and developments in the industry in which we operate are consistent with the forward-looking statements contained in such reports, those results or developments may not be indicative of results or developments in subsequent periods

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

For the treatment-regimen estimand, the mean body weight reductions from baseline at 72 weeks were 15.0%, 19.5%, and 20.9% in the tirzepatide 5, 10, and 15 mg groups, respectively, versus 3.1% in the placebo group

10.1002/dmrr.2413 61